Search
for
Sort by
Research 61–90 of 1000+
- Off-label use of biologics and janus kinase (JAK) inhibitors for scarring alopecias: a narrative review
- Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)
- Efficacy and safety of the oral Janus kinase 3/tyrosine kinase expressed in hepatocellular carcinoma family kinase inhibitor ritlecitinib over 24 months: integrated analysis of the ALLEGRO phase IIb/III and long-term phase III clinical studies in alopecia areata
- 33766 Efficacy of baricitinib in patients with various degrees of alopecia areata severity: Results from BRAVE-AA1 and BRAVE-AA2
- Janus kinase inhibitors for alopecia areata
- Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: A pilot study of 10 patients
- Efficacy of Janus kinase inhibitors in adult patients with alopecia areata
- Treatment of alopecia universalis with topical Janus kinase inhibitors – a double blind, placebo, and active controlled pilot study
- Iron Chelators in the Management of Autoimmune-Induced Alopecia: A Focus on Hypoxia-Inducible Factor 1 Modulation and Hair Restoration
- Evolution of Ritlecitinib Population Pharmacokinetic Models During Clinical Drug Development
- Alopecia areata: from immunopathogenesis to emerging therapeutic approaches
- New drugs under investigation for the treatment of alopecias
- Editorial: Exploring innovative therapies for rare inflammatory skin diseases
- Ruxolitinib 1.5% Topical Cream for the Treatment of Pediatric Alopecia Areata
- Markers of Venous Thromboembolism Risk in Patients with Alopecia Areata: Is There Anything to Worry about?
- Psychophysiological Mechanisms of Stress Impact on Hair Loss Processes
- Selective Janus kinase 1 inhibition resolves inflammation and restores hair growth offering a viable treatment option for alopecia areata
- Janus Kinase inhibitors in dermatology: a review
- BH21 Efficacy and safety of oral Janus kinase inhibitors in the treatment of alopecia areata: a systematic review and meta-analysis
- P718 Observational real-world evidence on the efficacy and safety of Janus Kinase inhibitors (JAKi) in the treatment of moderate to severe Active Ulcerative Colitis (UC)
- Exploring the efficacy of baricitinib in treating alopecia areata after failed Janus kinase inhibitor therapy
- Association of Janus kinase inhibitors with reduced depression in alopecia areata
- Treatment of alopecia areata with the janus kinase inhibitor upadacitinib: A retrospective cohort study
- SYSTEMATIC REVIEW OF ORAL JANUS KINASE INHIBITORS IN ALOPECIA AREATA: INSIGHTS FROM 2020 TO 2025 STUDIES
- The Role of Tofacitinib in the Management of Alopecia Totalis
- Chemotherapy-Induced Alopecia Beyond Cytotoxicity: Hair Follicle Immune Privilege Collapse and JAK-STAT Signaling
- Precision Dermatology: A Review of Molecular Biomarkers and Personalized Therapies
- 0975 Single-cell transcriptomic profiling reveals distinct immunopathogenic programs in alopecia totalis/universalis compared to patchy alopecia areata
- Hair growth–promoting effects of Enz_MoriL on human dermal papilla cells through modulation of the Wnt/β-Catenin and JAK-STAT signaling pathways
- Survey of pediatric dermatologist views on treatment for alopecia areata